stock-detail (SVON)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

Harlan Waksal, M.D. resigns as Chairman of the Board of Sevion Therapeutics

3/11/2016 03:00 am

[Business Wire] - Sevion Therapeutics, Inc. , a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr.

Sevion Therapeutics Reports First Quarter 2016 Financial Results

11/17/2015 10:03 pm

[at noodls] - Sevion Therapeutics, Inc. ('Sevion' or the 'Company')(OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological ...

Sevion Therapeutics Reports First Quarter 2016 Financial Results

11/17/2015 10:00 pm

[Business Wire] - Sevion Therapeutics, Inc. , a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal quarter ended September 30, 2015 .

Sevion Therapeutics Presents Cow Antibody Platform at Protein Discovery Summit

10/21/2015 10:01 am

[at noodls] - Sevion Therapeutics, Inc. ('Sevion' or the 'Company') (OTCBB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological ...

Sevion Therapeutics Presents Cow Antibody Platform at Protein Discovery Summit

10/21/2015 10:00 am

[Business Wire] - Sevion Therapeutics, Inc. , a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr.

Sevion Therapeutics Reports Fiscal Year 2015 Financial Results

10/14/2015 10:00 pm

[at noodls] - Sevion Therapeutics, Inc. ('Sevion' or the 'Company') (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological ...

Sevion Therapeutics Reports Fiscal Year 2015 Financial Results

10/14/2015 09:04 pm

[Business Wire] - Sevion Therapeutics, Inc. , a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal year ended June 30, 2015 and also provided an overview of corporate accomplishments and plans.

Sevion Therapeutics Presents Antibody Discovery Platform at International Conference

9/22/2015 10:01 am

[at noodls] - September 22, 2015 Sevion Therapeutics, Inc. ('Sevion' or the 'Company') (OTCBB:SVON), a biopharmaceutical company which discovers, develops, and acquires next-generation biologics for the treatment of ...

Sevion Therapeutics Presents Antibody Discovery Platform at International Conference

9/22/2015 10:00 am

[Business Wire] - Sevion Therapeutics, Inc. , a biopharmaceutical company which discovers, develops, and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr.

Sevion Therapeutics, Inc. Announces Close of Private Placement Financing for Gross Proceeds of Approximately $6.55 Million

8/3/2015 10:04 am

[at noodls] - August 03, 2015 Sevion Therapeutics, Inc. ('Sevion' or the 'Company') (OTCQB:SVON)today announced that on July 27, 2015 the Company closed a private placement with certain accredited investors (the 'Offering') ...

Sevion Therapeutics, Inc. Announces Close of Private Placement Financing for Gross Proceeds of Approximately $6.55 Million

8/3/2015 10:03 am

[Business Wire] - Sevion Therapeutics, Inc. today announced that on July 27, 2015 the Company closed a private placement with certain accredited investors whereby the Company sold units consisting of shares common stock or convertible preferred stock of the Company and warrants to purchase shares of common stock for aggregate gross proceeds of approximately $6,548,963.